| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardium | 19 | 2025 | 263 | 3.640 |
Why?
|
| Myocytes, Cardiac | 6 | 2025 | 183 | 2.820 |
Why?
|
| Myocardial Infarction | 5 | 2025 | 247 | 2.350 |
Why?
|
| Microbubbles | 11 | 2021 | 22 | 2.320 |
Why?
|
| Pyruvate Kinase | 4 | 2025 | 18 | 1.920 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 8 | 2019 | 88 | 1.900 |
Why?
|
| Heart | 11 | 2021 | 184 | 1.820 |
Why?
|
| Hypoxia-Inducible Factor 1 | 4 | 2021 | 12 | 1.710 |
Why?
|
| Myocardial Ischemia | 3 | 2021 | 83 | 1.570 |
Why?
|
| Mice, Knockout | 13 | 2025 | 1035 | 1.550 |
Why?
|
| Endothelium, Vascular | 9 | 2015 | 263 | 1.450 |
Why?
|
| Mice, Inbred C57BL | 18 | 2025 | 1869 | 1.370 |
Why?
|
| Mice | 42 | 2025 | 6644 | 1.350 |
Why?
|
| Animals | 65 | 2025 | 16992 | 1.250 |
Why?
|
| Ultrasonics | 6 | 2016 | 15 | 1.230 |
Why?
|
| Transcription, Genetic | 10 | 2019 | 592 | 1.170 |
Why?
|
| Gene Transfer Techniques | 5 | 2021 | 53 | 1.010 |
Why?
|
| Lipid Metabolism | 3 | 2025 | 148 | 1.000 |
Why?
|
| Atherosclerosis | 4 | 2021 | 169 | 0.970 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2019 | 30 | 0.930 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 2 | 2024 | 21 | 0.920 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 3 | 2024 | 8 | 0.890 |
Why?
|
| Oxidative Stress | 5 | 2025 | 1003 | 0.810 |
Why?
|
| Alternative Splicing | 2 | 2021 | 94 | 0.810 |
Why?
|
| MicroRNAs | 2 | 2020 | 518 | 0.800 |
Why?
|
| RNA, Messenger | 11 | 2020 | 1271 | 0.790 |
Why?
|
| Endothelin-1 | 4 | 2008 | 57 | 0.750 |
Why?
|
| Gene Expression Profiling | 5 | 2018 | 704 | 0.740 |
Why?
|
| Diabetic Angiopathies | 2 | 2015 | 26 | 0.740 |
Why?
|
| Endothelial Cells | 8 | 2022 | 329 | 0.710 |
Why?
|
| Male | 44 | 2025 | 23409 | 0.710 |
Why?
|
| Gene Expression Regulation | 9 | 2019 | 1070 | 0.680 |
Why?
|
| Amphetamine-Related Disorders | 2 | 2019 | 69 | 0.660 |
Why?
|
| Mice, Transgenic | 12 | 2021 | 665 | 0.650 |
Why?
|
| Mixed Function Oxygenases | 1 | 2020 | 31 | 0.650 |
Why?
|
| Up-Regulation | 3 | 2020 | 536 | 0.640 |
Why?
|
| Neovascularization, Physiologic | 5 | 2021 | 80 | 0.620 |
Why?
|
| Cytoskeletal Proteins | 1 | 2020 | 116 | 0.610 |
Why?
|
| Methamphetamine | 2 | 2019 | 166 | 0.600 |
Why?
|
| Myocardial Contraction | 1 | 2018 | 46 | 0.580 |
Why?
|
| Cardiomyopathies | 3 | 2022 | 65 | 0.580 |
Why?
|
| DNA-Binding Proteins | 3 | 2020 | 561 | 0.570 |
Why?
|
| Transfection | 5 | 2016 | 532 | 0.570 |
Why?
|
| Disease Models, Animal | 7 | 2020 | 1596 | 0.560 |
Why?
|
| Genome-Wide Association Study | 8 | 2020 | 423 | 0.560 |
Why?
|
| Galectin 3 | 2 | 2015 | 30 | 0.540 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2019 | 223 | 0.520 |
Why?
|
| Contrast Media | 7 | 2009 | 103 | 0.510 |
Why?
|
| Liver | 5 | 2021 | 511 | 0.490 |
Why?
|
| Factor IX | 1 | 2016 | 3 | 0.490 |
Why?
|
| Plasmids | 5 | 2021 | 244 | 0.490 |
Why?
|
| Marfan Syndrome | 4 | 2022 | 4 | 0.480 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 7 | 2011 | 310 | 0.470 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2007 | 96 | 0.470 |
Why?
|
| Echocardiography | 8 | 2017 | 167 | 0.470 |
Why?
|
| Drug Delivery Systems | 2 | 2009 | 277 | 0.440 |
Why?
|
| Signal Transduction | 10 | 2025 | 2157 | 0.430 |
Why?
|
| Loeys-Dietz Syndrome | 3 | 2023 | 3 | 0.430 |
Why?
|
| Registries | 6 | 2022 | 437 | 0.430 |
Why?
|
| Cardiomegaly | 3 | 2011 | 44 | 0.420 |
Why?
|
| Humans | 51 | 2023 | 43102 | 0.420 |
Why?
|
| Cardiovascular Diseases | 6 | 2020 | 749 | 0.410 |
Why?
|
| Heart Ventricles | 4 | 2016 | 123 | 0.410 |
Why?
|
| Vehicle Emissions | 2 | 2011 | 22 | 0.400 |
Why?
|
| Gluconates | 1 | 2012 | 5 | 0.390 |
Why?
|
| Hyperkalemia | 1 | 2012 | 13 | 0.390 |
Why?
|
| Aortic Aneurysm, Thoracic | 3 | 2017 | 6 | 0.390 |
Why?
|
| Cnidarian Venoms | 1 | 2012 | 24 | 0.380 |
Why?
|
| Doxorubicin | 3 | 2022 | 97 | 0.380 |
Why?
|
| Cardiovascular System | 1 | 2012 | 37 | 0.380 |
Why?
|
| Sonication | 3 | 2013 | 14 | 0.360 |
Why?
|
| Air Pollutants | 2 | 2011 | 130 | 0.360 |
Why?
|
| Lipase | 2 | 2002 | 20 | 0.340 |
Why?
|
| Gene Frequency | 6 | 2020 | 206 | 0.340 |
Why?
|
| Myoglobin | 3 | 2002 | 18 | 0.340 |
Why?
|
| Luciferases | 4 | 2005 | 71 | 0.340 |
Why?
|
| Inhalation Exposure | 1 | 2011 | 44 | 0.330 |
Why?
|
| Heart Valve Diseases | 4 | 2017 | 15 | 0.330 |
Why?
|
| Hypercholesterolemia | 1 | 2011 | 42 | 0.330 |
Why?
|
| Genetic Vectors | 5 | 2013 | 165 | 0.330 |
Why?
|
| Aorta | 5 | 2017 | 198 | 0.320 |
Why?
|
| Female | 25 | 2025 | 24698 | 0.320 |
Why?
|
| Neovascularization, Pathologic | 3 | 2021 | 139 | 0.320 |
Why?
|
| Cell Hypoxia | 3 | 2019 | 60 | 0.320 |
Why?
|
| Aortic Valve | 4 | 2017 | 38 | 0.320 |
Why?
|
| Particulate Matter | 1 | 2011 | 83 | 0.320 |
Why?
|
| Coronary Vessels | 2 | 2007 | 92 | 0.320 |
Why?
|
| Energy Metabolism | 3 | 2025 | 187 | 0.300 |
Why?
|
| Endocytosis | 2 | 2009 | 118 | 0.290 |
Why?
|
| Heart Failure | 2 | 2011 | 302 | 0.280 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 652 | 0.280 |
Why?
|
| Albumins | 4 | 2004 | 33 | 0.270 |
Why?
|
| Mitochondria, Heart | 2 | 2024 | 60 | 0.270 |
Why?
|
| Quantitative Trait Loci | 3 | 2013 | 88 | 0.270 |
Why?
|
| Transcription Factors | 5 | 2020 | 735 | 0.270 |
Why?
|
| Adenosine Triphosphate | 2 | 2024 | 206 | 0.270 |
Why?
|
| Glycolysis | 3 | 2018 | 71 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2008 | 92 | 0.260 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2007 | 51 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 760 | 0.260 |
Why?
|
| Coronary Artery Disease | 2 | 2017 | 163 | 0.250 |
Why?
|
| Muscle Cells | 1 | 2006 | 12 | 0.250 |
Why?
|
| Ischemic Preconditioning, Myocardial | 2 | 2021 | 11 | 0.250 |
Why?
|
| Reactive Oxygen Species | 3 | 2024 | 532 | 0.240 |
Why?
|
| Electrocardiography | 5 | 2020 | 185 | 0.240 |
Why?
|
| Blotting, Western | 3 | 2021 | 883 | 0.240 |
Why?
|
| Luminescent Proteins | 2 | 2006 | 68 | 0.240 |
Why?
|
| Aortic Diseases | 3 | 2017 | 34 | 0.220 |
Why?
|
| Thyroid Hormones | 1 | 2025 | 35 | 0.220 |
Why?
|
| Software | 3 | 2006 | 236 | 0.220 |
Why?
|
| Ehlers-Danlos Syndrome | 2 | 2022 | 4 | 0.220 |
Why?
|
| Macrophages | 3 | 2025 | 529 | 0.220 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2020 | 863 | 0.220 |
Why?
|
| DNA | 5 | 2011 | 592 | 0.220 |
Why?
|
| Hyperthyroidism | 1 | 2004 | 8 | 0.210 |
Why?
|
| Hemodynamics | 3 | 2017 | 100 | 0.210 |
Why?
|
| Calcium | 2 | 2018 | 491 | 0.210 |
Why?
|
| Calcium-Binding Proteins | 1 | 2024 | 81 | 0.210 |
Why?
|
| Heart Diseases | 3 | 2006 | 112 | 0.210 |
Why?
|
| Risk Factors | 9 | 2019 | 3994 | 0.210 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2014 | 183 | 0.210 |
Why?
|
| Interleukin-6 | 1 | 2025 | 165 | 0.210 |
Why?
|
| Lipids | 3 | 2013 | 256 | 0.210 |
Why?
|
| Inflammation | 2 | 2025 | 758 | 0.210 |
Why?
|
| Ultrasonic Therapy | 1 | 2003 | 4 | 0.210 |
Why?
|
| Smoking | 2 | 2013 | 1024 | 0.200 |
Why?
|
| Muscle Fibers, Fast-Twitch | 1 | 2003 | 7 | 0.200 |
Why?
|
| Muscle Fibers, Slow-Twitch | 1 | 2003 | 10 | 0.200 |
Why?
|
| Quantitative Trait, Heritable | 2 | 2013 | 27 | 0.190 |
Why?
|
| Lipopolysaccharides | 1 | 2004 | 239 | 0.190 |
Why?
|
| Physical Endurance | 1 | 2003 | 20 | 0.190 |
Why?
|
| Heart Atria | 1 | 2002 | 29 | 0.190 |
Why?
|
| Sex Factors | 4 | 2019 | 1028 | 0.190 |
Why?
|
| Glucose | 1 | 2024 | 244 | 0.190 |
Why?
|
| Physical Conditioning, Animal | 1 | 2003 | 33 | 0.190 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2003 | 70 | 0.190 |
Why?
|
| Time Factors | 5 | 2019 | 1857 | 0.190 |
Why?
|
| Altitude | 1 | 2002 | 10 | 0.180 |
Why?
|
| Muscle, Skeletal | 4 | 2015 | 316 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2012 | 734 | 0.180 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2021 | 74 | 0.170 |
Why?
|
| Models, Cardiovascular | 1 | 2021 | 98 | 0.170 |
Why?
|
| Genotype | 6 | 2020 | 800 | 0.170 |
Why?
|
| Green Fluorescent Proteins | 4 | 2014 | 209 | 0.170 |
Why?
|
| Genes, Reporter | 5 | 2006 | 148 | 0.160 |
Why?
|
| Aorta, Thoracic | 2 | 2017 | 31 | 0.160 |
Why?
|
| Microspheres | 5 | 2003 | 49 | 0.160 |
Why?
|
| Alleles | 5 | 2016 | 352 | 0.160 |
Why?
|
| Polymorphism, Genetic | 4 | 2002 | 201 | 0.160 |
Why?
|
| Oxygen | 2 | 2013 | 218 | 0.150 |
Why?
|
| Caveolin 1 | 2 | 2011 | 33 | 0.150 |
Why?
|
| Genetics, Population | 3 | 2013 | 121 | 0.150 |
Why?
|
| Species Specificity | 2 | 2019 | 286 | 0.150 |
Why?
|
| Genetic Variation | 1 | 2002 | 430 | 0.150 |
Why?
|
| Rats | 9 | 2006 | 3735 | 0.150 |
Why?
|
| Phospholipases A | 1 | 1999 | 9 | 0.150 |
Why?
|
| Platelet Activating Factor | 1 | 1999 | 9 | 0.150 |
Why?
|
| United States | 10 | 2018 | 5205 | 0.150 |
Why?
|
| Coronary Angiography | 1 | 1999 | 96 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 3 | 2005 | 455 | 0.140 |
Why?
|
| Infusions, Intravenous | 3 | 2009 | 53 | 0.140 |
Why?
|
| Coronary Disease | 1 | 1999 | 123 | 0.140 |
Why?
|
| Gene Expression | 7 | 2015 | 701 | 0.140 |
Why?
|
| Acute Coronary Syndrome | 1 | 2018 | 42 | 0.140 |
Why?
|
| Base Sequence | 6 | 2006 | 983 | 0.140 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2011 | 131 | 0.140 |
Why?
|
| Risk Assessment | 2 | 2019 | 863 | 0.140 |
Why?
|
| Fibroblasts | 3 | 2015 | 281 | 0.140 |
Why?
|
| Apoptosis | 2 | 2006 | 1568 | 0.140 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2017 | 25 | 0.140 |
Why?
|
| Doxycycline | 1 | 2017 | 32 | 0.130 |
Why?
|
| Isoenzymes | 1 | 2018 | 168 | 0.130 |
Why?
|
| Middle Aged | 11 | 2023 | 12222 | 0.130 |
Why?
|
| Phenotype | 5 | 2020 | 780 | 0.130 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2017 | 14 | 0.130 |
Why?
|
| Gene Deletion | 3 | 2011 | 168 | 0.130 |
Why?
|
| Drug Costs | 1 | 2017 | 35 | 0.130 |
Why?
|
| Influenza A virus | 1 | 2017 | 31 | 0.130 |
Why?
|
| Respiratory Mucosa | 1 | 2017 | 41 | 0.130 |
Why?
|
| Heart Conduction System | 1 | 2016 | 15 | 0.130 |
Why?
|
| Organ Specificity | 4 | 2004 | 141 | 0.130 |
Why?
|
| Long QT Syndrome | 1 | 2016 | 15 | 0.130 |
Why?
|
| Tissue Plasminogen Activator | 2 | 1994 | 21 | 0.130 |
Why?
|
| Patient Readmission | 1 | 2018 | 122 | 0.130 |
Why?
|
| Protein Binding | 1 | 2020 | 1082 | 0.130 |
Why?
|
| Glycoproteins | 1 | 2017 | 125 | 0.120 |
Why?
|
| Hemophilia B | 1 | 2016 | 2 | 0.120 |
Why?
|
| Linkage Disequilibrium | 4 | 2016 | 86 | 0.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 89 | 0.120 |
Why?
|
| Influenza, Human | 1 | 2017 | 92 | 0.120 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2015 | 8 | 0.120 |
Why?
|
| DNA Methylation | 1 | 2019 | 403 | 0.120 |
Why?
|
| Prothrombin Time | 1 | 2015 | 8 | 0.120 |
Why?
|
| Phosphoproteins | 1 | 2017 | 206 | 0.120 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2015 | 14 | 0.120 |
Why?
|
| Ultrasonography | 3 | 2005 | 135 | 0.110 |
Why?
|
| Blood Glucose | 2 | 2015 | 389 | 0.110 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 140 | 0.110 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 934 | 0.110 |
Why?
|
| NF-kappa B | 2 | 2008 | 358 | 0.110 |
Why?
|
| DNA, Complementary | 3 | 2005 | 196 | 0.110 |
Why?
|
| Cholesterol, HDL | 3 | 2013 | 99 | 0.110 |
Why?
|
| Adult | 10 | 2023 | 13872 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1998 | 587 | 0.110 |
Why?
|
| Osteogenesis | 1 | 2014 | 57 | 0.110 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 1994 | 23 | 0.100 |
Why?
|
| Fibrinolytic Agents | 1 | 1994 | 24 | 0.100 |
Why?
|
| Phosphorylation | 2 | 2015 | 986 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 2 | 2022 | 216 | 0.100 |
Why?
|
| Genome, Human | 2 | 2013 | 144 | 0.100 |
Why?
|
| Transposases | 1 | 2013 | 9 | 0.100 |
Why?
|
| Infant | 4 | 2017 | 1175 | 0.100 |
Why?
|
| In Situ Hybridization | 2 | 2004 | 138 | 0.100 |
Why?
|
| Glycogen | 1 | 2013 | 20 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2006 | 1766 | 0.100 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2012 | 197 | 0.100 |
Why?
|
| Transgenes | 2 | 2003 | 65 | 0.100 |
Why?
|
| Delayed-Action Preparations | 1 | 2013 | 74 | 0.100 |
Why?
|
| Insulin Resistance | 1 | 2015 | 201 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 299 | 0.100 |
Why?
|
| Aged | 7 | 2018 | 8214 | 0.100 |
Why?
|
| Reperfusion Injury | 1 | 2013 | 58 | 0.100 |
Why?
|
| Child, Preschool | 4 | 2017 | 1546 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1994 | 296 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 238 | 0.100 |
Why?
|
| Recovery of Function | 1 | 2013 | 107 | 0.100 |
Why?
|
| Fluorocarbons | 2 | 2004 | 42 | 0.100 |
Why?
|
| Tachycardia | 1 | 2012 | 11 | 0.090 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 160 | 0.090 |
Why?
|
| Retrospective Studies | 4 | 2022 | 2544 | 0.090 |
Why?
|
| Endothelium | 1 | 2011 | 28 | 0.090 |
Why?
|
| Central Nervous System Stimulants | 1 | 2013 | 180 | 0.090 |
Why?
|
| Cryosurgery | 1 | 2011 | 7 | 0.090 |
Why?
|
| Cells, Cultured | 4 | 2017 | 1621 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2011 | 21 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2004 | 257 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2011 | 33 | 0.080 |
Why?
|
| Adolescent | 6 | 2017 | 6081 | 0.080 |
Why?
|
| Flow Cytometry | 3 | 2011 | 411 | 0.080 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2011 | 97 | 0.080 |
Why?
|
| Young Adult | 6 | 2017 | 5080 | 0.080 |
Why?
|
| Cloning, Molecular | 2 | 1997 | 314 | 0.080 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 74 | 0.080 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 127 | 0.080 |
Why?
|
| Receptor, TIE-2 | 2 | 2011 | 2 | 0.080 |
Why?
|
| Myosin Subfragments | 1 | 1989 | 2 | 0.080 |
Why?
|
| Air Pollution | 1 | 2011 | 87 | 0.080 |
Why?
|
| Smad3 Protein | 2 | 2022 | 12 | 0.080 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 149 | 0.080 |
Why?
|
| Aging | 2 | 2006 | 783 | 0.080 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 107 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2011 | 29 | 0.080 |
Why?
|
| Selenoproteins | 1 | 2011 | 155 | 0.080 |
Why?
|
| Femoral Artery | 1 | 2009 | 12 | 0.080 |
Why?
|
| MEDLINE | 2 | 2006 | 9 | 0.080 |
Why?
|
| Dextrans | 1 | 2009 | 29 | 0.070 |
Why?
|
| Child | 4 | 2017 | 3443 | 0.070 |
Why?
|
| Integrases | 2 | 2011 | 28 | 0.070 |
Why?
|
| Pressure | 1 | 2009 | 50 | 0.070 |
Why?
|
| Receptor, Endothelin A | 1 | 2008 | 3 | 0.070 |
Why?
|
| Receptor, Endothelin B | 1 | 2008 | 4 | 0.070 |
Why?
|
| Endothelins | 1 | 2008 | 7 | 0.070 |
Why?
|
| Receptors, Endothelin | 1 | 2008 | 7 | 0.070 |
Why?
|
| Calcineurin | 1 | 2008 | 23 | 0.070 |
Why?
|
| Vitamin D | 1 | 2011 | 196 | 0.070 |
Why?
|
| Phagocytosis | 1 | 2009 | 86 | 0.070 |
Why?
|
| Biological Transport | 1 | 2009 | 204 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 107 | 0.070 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 98 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2008 | 137 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2008 | 105 | 0.070 |
Why?
|
| Fluorescent Dyes | 1 | 2009 | 182 | 0.070 |
Why?
|
| Adiponectin | 1 | 2008 | 59 | 0.070 |
Why?
|
| Th2 Cells | 1 | 2007 | 62 | 0.070 |
Why?
|
| Blotting, Northern | 2 | 2003 | 150 | 0.070 |
Why?
|
| Mucins | 1 | 2008 | 73 | 0.070 |
Why?
|
| Antioxidants | 1 | 2011 | 443 | 0.070 |
Why?
|
| Allergens | 1 | 2007 | 65 | 0.070 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2006 | 6 | 0.060 |
Why?
|
| Consensus Sequence | 1 | 2006 | 21 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 259 | 0.060 |
Why?
|
| Islets of Langerhans | 1 | 2006 | 16 | 0.060 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2006 | 22 | 0.060 |
Why?
|
| Isoproterenol | 1 | 2006 | 39 | 0.060 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2006 | 45 | 0.060 |
Why?
|
| Prevalence | 3 | 2017 | 1612 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2007 | 456 | 0.060 |
Why?
|
| Receptors, IgG | 1 | 2005 | 53 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2022 | 1600 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2005 | 75 | 0.060 |
Why?
|
| Melatonin | 1 | 2006 | 82 | 0.060 |
Why?
|
| Cell Cycle Proteins | 2 | 1998 | 241 | 0.060 |
Why?
|
| Nuclear Proteins | 2 | 1998 | 333 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 2853 | 0.060 |
Why?
|
| Ultrasonography, Interventional | 2 | 2005 | 20 | 0.060 |
Why?
|
| Conserved Sequence | 2 | 2002 | 122 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2004 | 2 | 0.060 |
Why?
|
| Lipocalins | 1 | 2004 | 6 | 0.050 |
Why?
|
| Computer Systems | 1 | 2004 | 19 | 0.050 |
Why?
|
| Smoke | 1 | 2005 | 42 | 0.050 |
Why?
|
| Acute-Phase Proteins | 1 | 2004 | 15 | 0.050 |
Why?
|
| Oncogene Proteins | 1 | 2004 | 21 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2005 | 167 | 0.050 |
Why?
|
| DNA Primers | 1 | 2005 | 294 | 0.050 |
Why?
|
| Rats, Zucker | 2 | 2003 | 24 | 0.050 |
Why?
|
| Databases, Bibliographic | 1 | 2004 | 8 | 0.050 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2004 | 40 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2011 | 719 | 0.050 |
Why?
|
| Fibroblast Growth Factors | 1 | 2004 | 36 | 0.050 |
Why?
|
| Smad2 Protein | 2 | 2015 | 11 | 0.050 |
Why?
|
| Skin Diseases, Genetic | 1 | 2023 | 1 | 0.050 |
Why?
|
| Vascular Malformations | 1 | 2023 | 1 | 0.050 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2005 | 140 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2004 | 207 | 0.050 |
Why?
|
| Triiodothyronine | 1 | 2004 | 36 | 0.050 |
Why?
|
| Information Storage and Retrieval | 1 | 2004 | 35 | 0.050 |
Why?
|
| Natural Language Processing | 1 | 2004 | 21 | 0.050 |
Why?
|
| Joint Instability | 1 | 2023 | 5 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2004 | 42 | 0.050 |
Why?
|
| Recombination, Genetic | 1 | 2004 | 95 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2003 | 62 | 0.050 |
Why?
|
| Asthma | 1 | 2007 | 416 | 0.050 |
Why?
|
| Lung | 1 | 2006 | 492 | 0.050 |
Why?
|
| Periodicals as Topic | 1 | 2004 | 52 | 0.050 |
Why?
|
| Echocardiography, Doppler | 1 | 2003 | 41 | 0.050 |
Why?
|
| Algorithms | 2 | 2004 | 509 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2003 | 45 | 0.050 |
Why?
|
| Myogenic Regulatory Factors | 1 | 2002 | 2 | 0.050 |
Why?
|
| Arteries | 1 | 2023 | 81 | 0.050 |
Why?
|
| Troponin T | 1 | 2002 | 10 | 0.050 |
Why?
|
| Binding Sites | 2 | 2002 | 671 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2005 | 256 | 0.050 |
Why?
|
| Stanozolol | 1 | 2002 | 1 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 1124 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 526 | 0.050 |
Why?
|
| RNA | 1 | 2004 | 266 | 0.050 |
Why?
|
| Viral Proteins | 1 | 2004 | 190 | 0.050 |
Why?
|
| Tibet | 1 | 2002 | 1 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2004 | 112 | 0.050 |
Why?
|
| Anabolic Agents | 1 | 2002 | 20 | 0.050 |
Why?
|
| Triglycerides | 2 | 2013 | 147 | 0.050 |
Why?
|
| Incidence | 2 | 2016 | 1078 | 0.040 |
Why?
|
| Exons | 1 | 2002 | 92 | 0.040 |
Why?
|
| Bromodeoxyuridine | 1 | 2001 | 25 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2002 | 114 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2002 | 113 | 0.040 |
Why?
|
| Mice, Inbred ICR | 1 | 2001 | 44 | 0.040 |
Why?
|
| Hawaii | 2 | 2018 | 2011 | 0.040 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2001 | 76 | 0.040 |
Why?
|
| Molecular Sequence Data | 5 | 2000 | 1542 | 0.040 |
Why?
|
| Myeloid Cells | 2 | 2011 | 31 | 0.040 |
Why?
|
| Cell Line | 4 | 2015 | 1410 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2017 | 1759 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2000 | 515 | 0.040 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2000 | 9 | 0.040 |
Why?
|
| Cell Division | 1 | 2001 | 311 | 0.040 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2000 | 36 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2001 | 152 | 0.040 |
Why?
|
| Genes | 1 | 2000 | 56 | 0.040 |
Why?
|
| Lac Operon | 1 | 2000 | 21 | 0.040 |
Why?
|
| Genomics | 1 | 2002 | 293 | 0.040 |
Why?
|
| beta-Galactosidase | 1 | 2000 | 37 | 0.040 |
Why?
|
| Alu Elements | 1 | 2000 | 12 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2001 | 352 | 0.040 |
Why?
|
| DNA Replication | 2 | 1998 | 148 | 0.040 |
Why?
|
| Microscopy, Confocal | 2 | 2014 | 224 | 0.040 |
Why?
|
| Molecular Chaperones | 1 | 2020 | 70 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2020 | 104 | 0.040 |
Why?
|
| Models, Animal | 2 | 2015 | 151 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 1081 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 1999 | 61 | 0.040 |
Why?
|
| Heparin | 1 | 1999 | 40 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 150 | 0.040 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 1999 | 4 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2020 | 224 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2000 | 307 | 0.040 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1998 | 12 | 0.030 |
Why?
|
| Guanylate Cyclase | 1 | 1998 | 21 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2017 | 14 | 0.030 |
Why?
|
| Elastin | 1 | 2017 | 40 | 0.030 |
Why?
|
| Matrix Metalloproteinases | 1 | 2017 | 49 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 616 | 0.030 |
Why?
|
| Aortic Aneurysm | 1 | 2017 | 5 | 0.030 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 10 | 0.030 |
Why?
|
| Lovastatin | 1 | 2017 | 9 | 0.030 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1997 | 12 | 0.030 |
Why?
|
| Crystallography | 1 | 1997 | 8 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1997 | 11 | 0.030 |
Why?
|
| Simvastatin | 1 | 2017 | 29 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 317 | 0.030 |
Why?
|
| Sequence Analysis | 1 | 2016 | 26 | 0.030 |
Why?
|
| Heart Defects, Congenital | 1 | 2017 | 72 | 0.030 |
Why?
|
| Carbon Monoxide | 1 | 1997 | 47 | 0.030 |
Why?
|
| Turner Syndrome | 1 | 2016 | 2 | 0.030 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2016 | 6 | 0.030 |
Why?
|
| Aorta, Abdominal | 1 | 2016 | 17 | 0.030 |
Why?
|
| Cell Cycle | 1 | 1998 | 346 | 0.030 |
Why?
|
| Activin Receptors, Type I | 1 | 2015 | 3 | 0.030 |
Why?
|
| Activins | 1 | 2015 | 8 | 0.030 |
Why?
|
| Dioxoles | 1 | 2015 | 8 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2017 | 171 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 375 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 179 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2015 | 26 | 0.030 |
Why?
|
| Organ Size | 1 | 2016 | 170 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 1998 | 321 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2000 | 88 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2016 | 92 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2015 | 109 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2017 | 209 | 0.030 |
Why?
|
| AMP Deaminase | 1 | 2015 | 1 | 0.030 |
Why?
|
| Benzamides | 1 | 2015 | 81 | 0.030 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 1995 | 7 | 0.030 |
Why?
|
| Citrate (si)-Synthase | 1 | 1995 | 10 | 0.030 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1995 | 12 | 0.030 |
Why?
|
| Citric Acid Cycle | 1 | 1995 | 7 | 0.030 |
Why?
|
| Mitochondrial ADP, ATP Translocases | 1 | 1995 | 8 | 0.030 |
Why?
|
| Proton-Translocating ATPases | 1 | 1995 | 17 | 0.030 |
Why?
|
| Nucleotides | 1 | 2015 | 37 | 0.030 |
Why?
|
| Ribonucleases | 1 | 1995 | 32 | 0.030 |
Why?
|
| Computational Biology | 2 | 2012 | 327 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1995 | 64 | 0.030 |
Why?
|
| Virus Replication | 1 | 2017 | 318 | 0.030 |
Why?
|
| Oxidative Phosphorylation | 1 | 1995 | 60 | 0.030 |
Why?
|
| Calmodulin | 1 | 1995 | 47 | 0.030 |
Why?
|
| Ischemia | 1 | 2015 | 47 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 1997 | 1180 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2014 | 35 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 1067 | 0.030 |
Why?
|
| Dogs | 1 | 1995 | 204 | 0.030 |
Why?
|
| Osteoblasts | 1 | 2014 | 44 | 0.030 |
Why?
|
| Fibrinolysis | 1 | 1994 | 2 | 0.030 |
Why?
|
| Medicare | 1 | 2017 | 332 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2014 | 79 | 0.030 |
Why?
|
| High-Energy Shock Waves | 1 | 2013 | 1 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 1154 | 0.030 |
Why?
|
| CHO Cells | 1 | 1994 | 123 | 0.030 |
Why?
|
| Protein Engineering | 1 | 1994 | 49 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2013 | 37 | 0.030 |
Why?
|
| Cricetinae | 1 | 1994 | 241 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2013 | 11 | 0.030 |
Why?
|
| DNA Transposable Elements | 1 | 2013 | 55 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2013 | 73 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2014 | 114 | 0.020 |
Why?
|
| Cardiotonic Agents | 1 | 2013 | 40 | 0.020 |
Why?
|
| Population Groups | 1 | 2013 | 59 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 118 | 0.020 |
Why?
|
| Mutation | 1 | 1998 | 1177 | 0.020 |
Why?
|
| Metagenomics | 1 | 2012 | 46 | 0.020 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 1992 | 22 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 1992 | 70 | 0.020 |
Why?
|
| Tyrosine | 1 | 1992 | 120 | 0.020 |
Why?
|
| Endocrine System | 1 | 2011 | 12 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1992 | 146 | 0.020 |
Why?
|
| Tetracycline | 1 | 2011 | 17 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2011 | 43 | 0.020 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2011 | 5 | 0.020 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2011 | 5 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2011 | 34 | 0.020 |
Why?
|
| Molecular Epidemiology | 1 | 2011 | 59 | 0.020 |
Why?
|
| Microvessels | 1 | 2011 | 31 | 0.020 |
Why?
|
| Cell Separation | 1 | 2011 | 94 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 196 | 0.020 |
Why?
|
| Microcirculation | 1 | 2011 | 40 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 48 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2011 | 67 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2011 | 67 | 0.020 |
Why?
|
| Pericytes | 1 | 2011 | 21 | 0.020 |
Why?
|
| Hypertension | 1 | 1998 | 835 | 0.020 |
Why?
|
| Pregnancy | 1 | 2016 | 1772 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 861 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 62 | 0.020 |
Why?
|
| Fibrosis | 1 | 2011 | 169 | 0.020 |
Why?
|
| Vitamins | 1 | 2011 | 81 | 0.020 |
Why?
|
| Collagen | 1 | 2011 | 181 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2011 | 173 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 458 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1989 | 42 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2013 | 666 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1989 | 70 | 0.020 |
Why?
|
| Gene Library | 1 | 1989 | 62 | 0.020 |
Why?
|
| Epithelium | 1 | 1989 | 78 | 0.020 |
Why?
|
| Body Weight | 1 | 2011 | 429 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2011 | 213 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 3156 | 0.020 |
Why?
|
| Chickens | 1 | 1989 | 161 | 0.020 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2007 | 6 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2011 | 434 | 0.020 |
Why?
|
| Fungal Proteins | 2 | 2000 | 142 | 0.020 |
Why?
|
| Interleukins | 1 | 2007 | 40 | 0.020 |
Why?
|
| Pulmonary Fibrosis | 1 | 2007 | 38 | 0.020 |
Why?
|
| Metalloproteases | 1 | 2006 | 18 | 0.020 |
Why?
|
| Heme Oxygenase-1 | 1 | 2006 | 52 | 0.020 |
Why?
|
| C-Peptide | 1 | 2006 | 7 | 0.020 |
Why?
|
| Hexokinase | 1 | 2006 | 10 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2006 | 117 | 0.020 |
Why?
|
| U937 Cells | 1 | 2005 | 31 | 0.010 |
Why?
|
| Serum Amyloid P-Component | 1 | 2005 | 21 | 0.010 |
Why?
|
| Avidin | 1 | 2005 | 4 | 0.010 |
Why?
|
| Arterioles | 1 | 2005 | 19 | 0.010 |
Why?
|
| Capillaries | 1 | 2005 | 27 | 0.010 |
Why?
|
| Apolipoproteins E | 1 | 2006 | 138 | 0.010 |
Why?
|
| Acetylcholine | 1 | 2005 | 77 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2005 | 49 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2011 | 1455 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2005 | 200 | 0.010 |
Why?
|
| Insulin | 1 | 2006 | 258 | 0.010 |
Why?
|
| Cattle | 1 | 2005 | 498 | 0.010 |
Why?
|
| Computing Methodologies | 1 | 2004 | 5 | 0.010 |
Why?
|
| Database Management Systems | 1 | 2004 | 19 | 0.010 |
Why?
|
| Pattern Recognition, Automated | 1 | 2004 | 32 | 0.010 |
Why?
|
| Semantics | 1 | 2004 | 29 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 306 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2005 | 386 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2003 | 575 | 0.010 |
Why?
|
| Human Genome Project | 1 | 2000 | 7 | 0.010 |
Why?
|
| Yeasts | 1 | 2000 | 19 | 0.010 |
Why?
|
| Nucleic Acid Conformation | 1 | 2000 | 154 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2000 | 440 | 0.010 |
Why?
|
| Temperature | 1 | 2000 | 313 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 611 | 0.010 |
Why?
|
| Transcription Factor DP1 | 1 | 1998 | 3 | 0.010 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 1 | 1998 | 3 | 0.010 |
Why?
|
| E2F Transcription Factors | 1 | 1998 | 11 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 1997 | 12 | 0.010 |
Why?
|
| Schizosaccharomyces pombe Proteins | 1 | 1997 | 14 | 0.010 |
Why?
|
| Xenopus | 1 | 1997 | 48 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1997 | 199 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1997 | 267 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1997 | 383 | 0.010 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 1992 | 10 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 50 | 0.010 |
Why?
|
| Hemolysis | 1 | 1992 | 60 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 1992 | 219 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1992 | 186 | 0.010 |
Why?
|
| Protein Conformation | 1 | 1992 | 416 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1992 | 518 | 0.010 |
Why?
|
| Kinetics | 1 | 1992 | 695 | 0.010 |
Why?
|
| Models, Molecular | 1 | 1992 | 876 | 0.000 |
Why?
|